Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (11546)	11/20/1997 5:58:00 PM
From: Proton	Respond to of 32384

Re: The Software Guy's Education Continues... Thanks! You've clarified the importance of point of action, especially in diabetes (now, I didn't say I understood it all :-] ). Prandin sounds underdeveloped, in one of the references a clinician mentioned their lack of even a clear dose. Yeah, for a fast-track recommendation for full approval, I'll grant you there was more than a little skepticism from the Metabolic Committee, esp. cardio side effects and hypoglycemia frequency. Any idea as to whether the FDA will approve before those studies are completed? I appreciate your reply. I approach investing in an area away from my regular areas -- computer tech and value investing -- with some concern. I've sometimes paid a high toll for wandering off my familiar roads. I just believe I have start understanding this field for investing during the next 10 years. Pý